Luna Musib

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess et al. · The Lancet Oncology · 2018 · 647 citations · Full text

Oncology, Body Composition, Cancer Management +8

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

Wolfgang Wick, Vinay K. Puduvalli, Marc C. Chamberlain et al. · Journal of Clinical Oncology · 2010 · 507 citations

The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

Jeremy R. Graff, Ann M. McNulty, Kimberly R. Hanna et al. · Cancer Research · 2005 · 435 citations · Full text

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

Antoni Ribas, René González, Anna C. Pavlick et al. · The Lancet Oncology · 2014 · 293 citations

Phase 1B, Medicine, Melanoma +7

Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Michael J. Robertson, Brad S. Kahl, Julie M. Vose et al. · Journal of Clinical Oncology · 2007 · 230 citations